Adjuvant chemotherapy is in general successful in reducing TNBC recurrence because it can kill proliferating DTCs, and hence incipient metastases, whereas it provides limited benefit to ER+ BC patients because the target cells have low proliferative indices37. Here, ESR1 is linked to breast cancer.